The biology of RNA interference has greatly facilitated analysis ... kinase inhibition RNAi typically involves generation of an siRNA or a small hairpin RNA (shRNA) that directs cleavage and ...

Efficient RNA interference in Caenorhabditis elegans ... 3 for a review). First, secondary siRNA has a 5′ triphosphate, precluding cloning methods that rely on a single 5′ phosphate.

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

An RNA interference (RNAi ... s drugs employ what she described as a divalent structure in which two small-interfering RNA (siRNA) duplexes are joined by a linker. This structure enable the ...

View Full Profile. Learn about our Editorial Policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat ... the delivery of both mRNA and siRNA in vivo and in vitro to enhance and disrupt ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to ... to show delivery of both mRNA and siRNA in vivo and in vitro, to enhance ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.